594P The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
N. Izawa(St. Marianna University School of Medicine), Yu Sunakawa(St. Marianna University School of Medicine), Wataru Ichikawa(Showa University Fujigaoka Hospital), Masashi Fujii(Nihon University), Yoshinori Kagawa(Osaka International Cancer Institute), Takashi Sagawa(National Hospital Organization Hokkaido Medical Center), Hisanobu Oda(Saiseikai Kumamoto Hospital), Kokoro Kobayashi(Kariya Toyota General Hospital), Tatsushi Shingai(Kinki Central Hospital), Michio Nakamura(Sapporo City General Hospital), Masahito Kotaka(Shimizu (Japan)), Yosuke Kumekawa, Takashi Kawai(Himeji Red Cross Hospital), Tatsuya Okuno(Kindai University), Masahiro Takeuchi(The University of Tokyo), Takashi Mine(Nagasaki Medical Center), Satoshi Yuki(Hokkaido University Hospital), Hironaga Satake(Kobe City Medical Center General Hospital), Toshihiro Kudo(Osaka International Cancer Institute)
Cited by 1
Related Papers
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
|Journal of Clinical Oncology|2014|777
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Implications of Nectin-like Molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in Cell-Cell Adhesion and Transmembrane Protein Localization in Epithelial Cells
|Journal of Biological Chemistry|2003|231
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
|Frontiers in Oncology|2019|199
Tage4/Nectin-like Molecule-5 Heterophilically trans-Interacts with Cell Adhesion Molecule Nectin-3 and Enhances Cell Migration
|Journal of Biological Chemistry|2003|130